Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Supreme Court Asked To Review Timing Of Biosimilar Entry

This article was originally published in The Pink Sheet Daily

Executive Summary

In Zarxio case, Sandoz petitions high court to determine whether notice of biosimilar commercial marketing can be given before FDA approval; court may await rulings in pending cases interpreting the biosimilars statute.


Related Content

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Biosimilar Launch Notification May Head Back To Court


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts